Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fondaparinux. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINC1 known ✓ | P01008 | 2/20 | 0.49 |
| ▸ | F10 | P00742 | 4/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | BDNF | P23560 | 3/20 | 0.47 |
| ▸ | PTN | P21246 | 2/20 | 0.47 |
| ▸ | MDK | P21741 | 2/20 | 0.47 |
| ▸ | HPSE | Q9Y251 | 9/20 | 0.46 |
| ▸ | PF4 | P02776 | 2/20 | 0.45 |
| ▸ | FGF1 | P05230 | 1/20 | 0.44 |
| ▸ | IFNG | P01579 | 1/20 | 0.42 |
| ▸ | BMP2 | P12643 | 1/20 | 0.42 |
| ▸ | CCL2 | P13500 | 1/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
| ▸ | BMP6 | P22004 | 1/20 | 0.42 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.42 |
| ▸ | CCL11 | P51671 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | SELPLG | Q14242 | 1/20 | 0.42 |
| ▸ | SHH | Q15465 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fondaparinux SCHEMBL19619397 | 1.00 | F10 (1.00) | F10SERPINC1F2BDNFPTN | |
| Fondaparinux SCHEMBL17655218 | 1.00 | F10 (1.00) | F10SERPINC1F2BDNFPTN | |
| Fondaparinux SCHEMBL1650579 | 1.00 | F10 (1.00) | F10SERPINC1F2BDNFPTN | |
| Fondaparinux SCHEMBL15296579 | 1.00 | F10 (1.00) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL10148985 | 0.92 | F10 (0.85) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL13795898 | 0.92 | F10 (0.85) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL13130300 | 0.92 | F10 (0.84) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL15199336 | 0.90 | F10 (0.81) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL10157440 | 0.90 | F10 (0.81) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL18883211 | 0.90 | F10 (0.81) | F10SERPINC1F2BDNFPTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9259389-B2 | Pharmaceutical oral dosage form containing a synthetic oligosaccharide | ENDOTIS PHARMA (FR) | 2016-02-16 | — | — | US | disclosed |
| US-9259389-B2 | Pharmaceutical oral dosage form containing a synthetic oligosaccharide | ENDOTIS PHARMA (FR) | 2016-02-16 | — | — | US | disclosed |
| US-20120316132-A1 | PHARMACEUTICAL ORAL DOSAGE FORM CONTAINING A SYNTHETIC OLIGOSACCHARIDE | CATALENT FRANCE BEINHEIM SA | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316132-A1 | PHARMACEUTICAL ORAL DOSAGE FORM CONTAINING A SYNTHETIC OLIGOSACCHARIDE | LIPA, SORD, SI | SERPINC1 919/4885F10 948/4885F2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.